Want to see HK:1228 full AI Analyst Report?
Top Page
CANbridge Pharmaceuticals Inc.
(1228)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$2.00
▼(-20.63% Downside)
Action:Reiterated
Date:08/05/26
The score is primarily held down by weak financial performance—persistent operating losses, ongoing negative free cash flow, and negative equity—despite some improvement in 2025 (lower burn and debt). Technicals are slightly better in the short term but still weak over longer horizons, and valuation is not compelling given the elevated P/E and lack of dividend yield.
Positive Factors
Rare-disease specialization
A focused rare-disease strategy gives CANbridge a defined therapeutic and commercialization scope, centered on orphan-drug development, regulatory submissions, and specialty access. This specialization can support consistent resource allocation and a durable platform for building expertise across underserved indications.
Negative Factors
Contracting and unprofitable operations
Recent revenue contraction indicates weakening scale, while deeply negative EBIT margins show that the current cost base is not supported by operating revenue. Together, these trends limit the business’s ability to convert commercialization activity into durable operating profitability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Rare-disease specialization
A focused rare-disease strategy gives CANbridge a defined therapeutic and commercialization scope, centered on orphan-drug development, regulatory submissions, and specialty access. This specialization can support consistent resource allocation and a durable platform for building expertise across underserved indications.
Read all positive factors
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.10B
Dividend YieldN/A
Average Volume (3M)2.75M
Price to Earnings (P/E)34.1
Beta (1Y)1.06
Revenue Growth-8.00%
EPS Growth51.26%
CountryHK
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.05
Shares Outstanding597,723,300
10 Day Avg. Volume538,977
30 Day Avg. Volume2,747,931
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)-3.07
Price to Sales (P/S)21.02
P/FCF Ratio-27.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
Company Description
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzym...
How the Company Makes Money
CANbridge generally makes money through the development and commercialization of rare-disease drug assets in its target geographies. Key revenue streams typically include: (1) Product sales: revenue from selling approved therapies through specialt...
CANbridge Pharmaceuticals Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.98M | 85.10M | 102.87M | 78.97M | 31.16M |
| Gross Profit | 36.55M | 54.30M | 64.16M | 48.89M | 18.78M |
| EBITDA | -78.98M | -328.69M | -341.43M | -454.63M | -1.06B |
| Net Income | 14.82M | -442.62M | -378.84M | -483.48M | -1.08B |
Balance Sheet | |||||
| Total Assets | 165.46M | 116.81M | 395.36M | 702.04M | 892.52M |
| Cash, Cash Equivalents and Short-Term Investments | 66.65M | 10.50M | 137.49M | 451.16M | 745.82M |
| Total Debt | 16.09M | 135.78M | 141.93M | 155.28M | 52.10M |
| Total Liabilities | 507.36M | 591.30M | 435.15M | 393.49M | 199.13M |
| Stockholders Equity | -341.90M | -474.49M | -39.79M | 308.56M | 693.39M |
Cash Flow | |||||
| Free Cash Flow | -38.22M | -122.50M | -319.09M | -315.76M | -592.40M |
| Operating Cash Flow | -38.21M | -122.39M | -278.23M | -280.98M | -587.07M |
| Investing Cash Flow | 1.23M | 13.93M | -26.86M | -34.79M | 126.09M |
| Financing Cash Flow | 92.47M | -18.57M | -28.02M | -20.70M | 854.31M |
CANbridge Pharmaceuticals Inc. Technical Analysis
Negative
2.52
Price Trends
2.03
Negative
2.07
Negative
2.27
Negative
Market Momentum
-0.05
Positive
43.90
Neutral
10.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Negative. The current price of 2.52 is above the 20-day moving average (MA) of 1.98, above the 50-day MA of 2.03, and above the 200-day MA of 2.27, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 10.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1228.
CANbridge Pharmaceuticals Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$35.93B | 36.15 | 20.41% | ― | 32.63% | 8.87% | |
52 Neutral | HK$4.82B | 8.07 | 47.76% | ― | 286.20% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$8.10B | -42.05 | -10.27% | ― | -31.77% | -177.01% | |
46 Neutral | HK$34.13B | -75.42 | -7.32% | ― | 34.83% | 58.94% | |
44 Neutral | HK$7.96B | -71.58 | -9.49% | ― | 68.12% | 81.84% | |
42 Neutral | HK$1.10B | 34.11 | -3.95% | ― | -8.00% | 51.26% |
* Healthcare Sector Average
HK:1228
CANbridge Pharmaceuticals Inc.
1.89
-1.04
-35.49%
HK:9966
Alphamab Oncology
8.45
-2.41
-22.19%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
6.13
-4.72
-43.50%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.64
-17.28
-49.48%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.43
-7.31
-35.25%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
67.20
-13.90
-17.14%
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge boosts rare disease footprint after HK$200 million WuXi stake
Aug 28, 2026
CANbridge Pharmaceuticals reported interim results marked by a strategic HK$200 million investment from WuXi Biologics HealthCare Venture, which acquired a 16.27% stake and became the company’s second-largest shareholder. The proceeds are ea...
CANbridge Wins Taiwan NHIA Reimbursement for Rare Disease Drug Livmarli
Aug 17, 2026
CANbridge Pharmaceuticals Inc. announced that its rare disease drug Livmarli has received reimbursement approval from Taiwan’s National Health Insurance Administration. The coverage, effective September 1, 2026, applies to patients with Alag...
CANbridge sets August board meeting to approve 2026 interim results
Aug 17, 2026
CANbridge Pharmaceuticals Inc. has scheduled a board meeting for August 28, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The meeting will also authorize publication of these interim figures, a ro...
CANbridge Pharmaceuticals Refreshes Board and Committee Leadership With New Independent Director
Aug 5, 2026
CANbridge Pharmaceuticals Inc., a Hong Kong-listed biopharmaceutical company, has announced changes to its board and committee leadership. The firm relies on independent non-executive directors to oversee remuneration and audit functions, reflecti...
CANbridge Pharmaceuticals Details Board and Committee Structure
Aug 5, 2026
CANbridge Pharmaceuticals has outlined the composition of its board of directors, naming Chairman and Chief Executive Officer Dr. James Qun Xue as the sole executive director alongside two non-executive directors and four independent non-executive...
CANbridge Shareholders Unanimously Approve WuXi Biologics Service Agreement
Aug 3, 2026
CANbridge Pharmaceuticals shareholders have approved, by poll, an ordinary resolution endorsing the WuXi Biologics Service Procurement Framework Agreement at an extraordinary general meeting held on August 3, 2026. Under the approved framework, di...
CANbridge Advances North African Expansion for Gaucher Drug Gaurunning
Jul 30, 2026
CANbridge Pharmaceuticals has begun registration and commercial preparations to introduce its Gaucher disease therapy Gaurunning, a velaglucerase-beta enzyme replacement injection, into a key North African market, targeting a region with large unm...
CANbridge Calls Virtual EGM to Approve WuXi Biologics Service Framework
Jul 15, 2026
CANbridge Pharmaceuticals Inc. has called an extraordinary general meeting to be held virtually on August 3, 2026, where shareholders will vote on approving the WuXi Biologics Service Procurement Framework Agreement and its related transaction cap...
CANbridge delays shareholder circular on WuXi Biologics framework deal
Jul 9, 2026
CANbridge Pharmaceuticals has postponed the dispatch of a shareholder circular related to its service procurement framework agreement with WuXi Biologics, pushing the mailing date to on or before July 20, 2026. The delay, attributed to the need fo...
CANbridge Shareholders Approve All Resolutions at 2026 AGM
Jun 23, 2026
Shareholders of CANbridge Pharmaceuticals Inc. approved all resolutions at the company’s annual general meeting held on June 23, 2026, with each item passed by poll as an ordinary resolution. The agenda included adoption of the 2025 audited ...
CANbridge Sets New Connected Service Deals With WuXi Biologics and Baheal Medical
Jun 16, 2026
CANbridge Pharmaceuticals has entered into a service procurement framework agreement with WuXi Biologics, effective from June 16, 2026 to December 31, 2028, under which WuXi Biologics, a 16.21% shareholder, will continue to provide biologics-relat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.